Academy of Primary Care, Hull York Medical School, University of Hull, Hull, UK.
Liverpool Reviews and Implementation Group, Institute of Population Health, University of Liverpool, Liverpool, UK.
Health Technol Assess. 2022 Jul;26(32):1-148. doi: 10.3310/AAFO2475.
BACKGROUND: Tackling problematic polypharmacy requires tailoring the use of medicines to individual needs and circumstances. This may involve stopping medicines (deprescribing) but patients and clinicians report uncertainty on how best to do this. The TAILOR medication synthesis sought to help understand how best to support deprescribing in older people living with multimorbidity and polypharmacy. OBJECTIVES: We identified two research questions: (1) what evidence exists to support the safe, effective and acceptable stopping of medication in this patient group, and (2) how, for whom and in what contexts can safe and effective tailoring of clinical decisions related to medication use work to produce desired outcomes? We thus described three objectives: (1) to undertake a robust scoping review of the literature on stopping medicines in this group to describe what is being done, where and for what effect; (2) to undertake a realist synthesis review to construct a programme theory that describes 'best practice' and helps explain the heterogeneity of deprescribing approaches; and (3) to translate findings into resources to support tailored prescribing in clinical practice. DATA SOURCES: Experienced information specialists conducted comprehensive searches in MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Web of Science, EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports, Google (Google Inc., Mountain View, CA, USA) and Google Scholar (targeted searches). REVIEW METHODS: The scoping review followed the five steps described by the Joanna Briggs Institute methodology for conducting a scoping review. The realist review followed the methodological and publication standards for realist reviews described by the Realist And Meta-narrative Evidence Syntheses: Evolving Standards (RAMESES) group. Patient and public involvement partners ensured that our analysis retained a patient-centred focus. RESULTS: Our scoping review identified 9528 abstracts: 8847 were removed at screening and 662 were removed at full-text review. This left 20 studies (published between 2009 and 2020) that examined the effectiveness, safety and acceptability of deprescribing in adults (aged ≥ 50 years) with polypharmacy (five or more prescribed medications) and multimorbidity (two or more conditions). Our analysis revealed that deprescribing under research conditions mapped well to expert guidance on the steps needed for good clinical practice. Our findings offer evidence-informed support to clinicians regarding the safety, clinician acceptability and potential effectiveness of clinical decision-making that demonstrates a structured approach to deprescribing decisions. Our realist review identified 2602 studies with 119 included in the final analysis. The analysis outlined 34 context-mechanism-outcome configurations describing the knowledge work of tailored prescribing under eight headings related to organisational, health-care professional and patient factors, and interventions to improve deprescribing. We conclude that robust tailored deprescribing requires attention to providing an enabling infrastructure, access to data, tailored explanations and trust. LIMITATIONS: Strict application of our definition of multimorbidity during the scoping review may have had an impact on the relevance of the review to clinical practice. The realist review was limited by the data (evidence) available. CONCLUSIONS: Our combined reviews recognise deprescribing as a complex intervention and provide support for the safety of structured approaches to deprescribing, but also highlight the need to integrate patient-centred and contextual factors into best practice models. FUTURE WORK: The TAILOR study has informed new funded research tackling deprescribing in sleep management, and professional education. Further research is being developed to implement tailored prescribing into routine primary care practice. STUDY REGISTRATION: This study is registered as PROSPERO CRD42018107544 and PROSPERO CRD42018104176. FUNDING: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 26, No. 32. See the NIHR Journals Library website for further project information.
背景:解决有问题的多药治疗需要根据个人需求和情况调整药物的使用。这可能涉及停止用药(停药),但患者和临床医生报告说,不确定如何最好地做到这一点。TAILOR 药物综合研究旨在帮助了解如何最好地支持患有多种疾病和多药治疗的老年人停药。
目的:我们确定了两个研究问题:(1)有哪些证据支持在这组患者中安全、有效和可接受地停止用药,(2)如何、为谁以及在什么情况下可以安全有效地调整与用药相关的临床决策,以产生预期的结果?因此,我们描述了三个目标:(1)对该组患者停药的文献进行全面的范围综述,以描述正在做什么、在哪里做以及效果如何;(2)进行真实主义综合审查,构建一个描述“最佳实践”并有助于解释停药方法异质性的方案理论;(3)将研究结果转化为支持临床实践中个体化处方的资源。
数据来源:经验丰富的信息专家在 MEDLINE、护理和联合健康文献累积索引、Web of Science、EMBASE、Cochrane 图书馆(Cochrane 系统评价数据库、Cochrane 中心对照试验注册)、Joanna Briggs 研究所系统评价和实施报告数据库、Google(Google Inc.,山景城,CA,美国)和 Google Scholar(有针对性的搜索)中进行了全面搜索。
审查方法:范围综述遵循 Joanna Briggs 研究所进行范围综述的五个步骤。真实主义综述遵循真实主义和元叙述证据综合:演进标准(RAMESES)小组描述的真实主义综述和元叙述证据综合的方法和出版标准。患者和公众参与伙伴确保我们的分析保持以患者为中心的重点。
结果:我们的范围综述确定了 9528 篇摘要:在筛选阶段排除了 8847 篇,在全文审查阶段排除了 662 篇。这留下了 20 项研究(发表于 2009 年至 2020 年),研究了在患有多药治疗(五种或以上处方药)和多种疾病(两种或以上疾病)的成年人中停药的有效性、安全性和可接受性。我们的分析表明,在研究条件下的停药与专家指导的良好临床实践所需的步骤非常吻合。我们的研究结果为临床医生提供了有关安全、临床可接受性和潜在有效性的循证支持,展示了一种针对决策的结构化方法。我们的真实主义综述确定了 2602 项研究,其中 119 项被纳入最终分析。分析概述了 34 个上下文-机制-结果配置,描述了与组织、医疗保健专业人员和患者因素以及改善停药的干预措施有关的个体化处方的知识工作。我们得出结论,稳健的个体化停药需要关注提供一个使能的基础设施、获得数据、量身定制的解释和信任。
局限性:在范围综述中严格应用我们对多种疾病的定义可能会对综述与临床实践的相关性产生影响。真实主义综述受到现有数据(证据)的限制。
结论:我们的综合综述认识到停药是一种复杂的干预措施,并为结构化停药方法的安全性提供了支持,但也强调需要将以患者为中心和背景因素纳入最佳实践模型。
未来工作:TAILOR 研究为睡眠管理和专业教育中的停药研究提供了新的资金支持。正在开发进一步的研究,将个体化处方纳入常规初级保健实践。
注册:本研究在 PROSPERO CRD42018107544 和 PROSPERO CRD42018104176 中进行了注册,并将在 ; Vol. 26, No. 32 中全文发表。有关该项目的更多信息,请访问 NIHR 期刊库网站。
Health Technol Assess. 2022-7
Cochrane Database Syst Rev. 2022-2-1
Early Hum Dev. 2020-11
Health Soc Care Deliv Res. 2024-8
Front Public Health. 2025-4-16
Br J Gen Pract. 2022-1-27
Br J Clin Pharmacol. 2021-1
Eur J Intern Med. 2021-1
BJGP Open. 2020-8-25
Kunstliche Intell (Oldenbourg). 2020
Gerontol Geriatr Med. 2019-12-20